Mesa Laboratories, Inc. Form 10-Q Summary
Reporting period: The supplied filing covers the three and six months ended September 30, 2023, Mesa’s fiscal second quarter and first six months of fiscal 2024. The request metadata identifies “2022 Q2,” but the filing itself is for 2023 Q2. Financial statements are unaudited and presented in thousands, except per-share data.
Business Context
Mesa manufactures and sells life-science tools, quality-control products, consumables, instruments, and related services through four segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Approximately 49% of second-quarter and 48% of year-to-date revenue was earned outside the United States.
Financial Results and Liquidity
| Metric | Three months ended September 30, 2023 | Year-over-year change | Six months ended September 30, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $53.2 million | Down 10% | $103.8 million | Down 5% |
| Gross profit | $32.1 million | Down 12% | $63.3 million | Down 7% |
| Gross margin | 60.4% | Down approximately 2 percentage points | 61.0% | Down approximately 1 percentage point |
| Operating income (loss) | $(0.1) million | From $4.0 million income | $(0.7) million | From $(0.6) million |
| Net income (loss) | $(1.2) million | From $1.3 million income | $(1.8) million | From $(0.1) million loss |
| Diluted EPS | $(0.23) | From $0.24 | $(0.33) | From $(0.02) |
| Cash flow from operations | Not separately reported | — | $19.7 million | Up from $7.7 million |
Cash and cash equivalents were $35.6 million at September 30, 2023, compared with $32.9 million at March 31, 2023. Working capital was $77.8 million. Capital expenditures were $0.9 million in the first six months. Financing cash outflows included $13.0 million of debt repayment and $1.7 million of dividends.
The company had $172.5 million of 1.375% convertible senior notes due August 2025, with a net carrying value of $170.7 million. There was no outstanding balance under the $75.0 million credit facility at September 30, 2023, and Mesa was in compliance with its covenants. After period-end, the facility was increased to $125.0 million and Mesa borrowed $65.0 million at a reported current rate of 6.9% to partially fund the GKE acquisition.
Material Changes Versus the Prior Comparable Period
- Revenue declined primarily because of weaker discretionary capital-equipment demand, the prior-year loss of significant Clinical Genomics customer Sema4, and macroeconomic pressure.
- Sterilization and Disinfection Control revenue increased 1% in the quarter and 4% year to date, while Calibration Solutions revenue increased 1% and 6%, respectively.
- Clinical Genomics revenue declined 16% in the quarter and 12% year to date. Excluding Sema4, management estimated revenue was approximately 3% lower for the quarter and flat year to date.
- Biopharmaceutical Development revenue declined 24% in the quarter and 17% year to date, mainly from lower hardware demand. Consumables and service revenue continued to grow.
- Operating expenses declined 1% in the quarter and 6% year to date, reflecting lower stock-based compensation and cost-containment actions. The company incurred approximately $0.35 million of reduction-in-force costs and expects approximately $2.0 million of annual savings beginning in fiscal third quarter.
- Foreign-currency translation produced an after-tax comprehensive loss impact of $1.4 million in the quarter and $8.0 million year to date.
Outlook, Transactions, Risks, and Unusual Items
On October 14, 2023, Mesa completed the acquisition of GKE GmbH, SAL GmbH, and, subject to Chinese regulatory approvals, Beijing GKE Science & Technology Co. Ltd. Total cash consideration was €85.0 million, subject to customary adjustments. GKE results will be consolidated beginning in fiscal third quarter 2024. Purchase-price accounting was incomplete as of the filing date. Mesa funded the transaction with cash on hand and $65.0 million of new credit-facility borrowings.
Management cited continued high interest rates, inflation, economic uncertainty, softening capital-equipment purchases, potential Chinese economic slowdown, foreign-exchange movements, supply-chain and labor risks, competition, regulatory changes, product acceptance, acquisition integration, cybersecurity, legal and contingent liabilities, and tax uncertainty. Management stated that supply-chain disruptions and labor shortages had largely abated during the first six months.
The company expects to pay $1.5 million related to contingent consideration for the Belyntic acquisition as specified patents are issued. GKE obligations include €8.5 million payable 18 months after closing, subject to indemnification adjustments, and an additional €5.0 million contingent on Chinese regulatory approvals.
Mesa paid and declared a quarterly dividend of $0.16 per share and announced another $0.16 dividend payable December 15, 2023. Management stated that operating cash flow, available credit, and other liquidity sources are expected to fund ongoing requirements, debt interest, dividends, and capital expenditures.
Previously reported material weaknesses related to fair-value calculations and goodwill-impairment assessments were deemed remediated as of September 30, 2023. Disclosure controls were assessed as effective. No material legal reserves or impairments were recorded during the reported periods.
Key Facts for Investors to Verify
- Confirm the intended reporting period because the filing is for September 30, 2023, not 2022 Q2.
- Assess the financial impact, integration progress, financing cost, and purchase accounting for the GKE acquisition.
- Monitor recovery or further deterioration in Biopharmaceutical Development and Clinical Genomics demand, including the effects of lost Sema4 revenue and China exposure.
- Verify whether cost-containment measures and the reduction in force deliver the expected approximately $2.0 million of annual savings.
- Review liquidity and leverage after the $65.0 million GKE-related borrowing, including the 2025 convertible-note maturity and credit-facility covenants.
- Track foreign-exchange sensitivity, interest-rate exposure, patent-related Belyntic payments, and contingent GKE consideration.